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Abstract
Background: Diffuse axonal injury in patients with traumatic brain injury (TBI) can be associated with morbidity 
ranging from cognitive difficulties to coma. Magnetic resonance imaging scans now allow early detection of axonal 
injury following TBI, and have linked cognitive disability in these patients to white matter signal changes. However, 
little is known about the pathophysiology of this white matter injury, and the role of microglial activation in this 
process. It is increasingly recognized that microglia constitute a heterogeneous population with diverse roles following 
injury. In the present studies, we tested the hypothesis that following diffuse axonal injury involving the corpus 
callosum, there is upregulation of a subpopulation of microglia that express the lectin galectin-3/Mac-2 and are 
involved in myelin phagocytosis.
Methods: Adult mice were subject to midline closed skull injury or sham operation and were sacrificed 1, 8, 14 or 28 
days later. Immunohistochemistry and immunofluorescence techniques were used to analyze patterns of labelling 
within the corpus callosum qualitatively and quantitatively.
Results: Activated microglia immunoreactive for galectin-3/Mac-2 were most abundant 1 day following injury. Their 
levels were attenuated at later time points after TBI but still were significantly elevated compared to sham animals. 
Furthermore, the majority of galectin-3/Mac-2+ microglia were immunoreactive for nerve growth factor in both sham 
and injured animals.
Conclusions: Our results suggest that galectin-3/Mac-2+ microglia play an important role in the pathogenesis of 
diffuse axonal injury both acutely and chronically and that they mediate their effects, at least in part by releasing nerve 
growth factor.
Background
Traumatic brain injury (TBI) is a leading cause of mortal-
ity and morbidity in Western industrialized nations and
poses significant financial and medical burden to society
[1]. Neurologic morbidity among survivors is high and
includes cognitive impairment, dementia, epilepsy and
depression [2-4]. Magnetic resonance imaging (MRI) of
survivors with neurocognitive deficits show significant
injury to the subcortical white matter, suggesting that
damage to these tracts may contribute to deficits in corti-
cal information processing observed in humans [5]. Path-
ological changes have been observed using diffusion
tensor MRI even in patients with mild TBI who have no
evidence of overt hemorrhage within the white matter
[6]. However, little is known about the role of microglia in
the pathophysiology of white matter injury following TBI.
The dual role of microglia following injury is now well-
recognized. For example, within the spinal cord, two
functionally distinct populations of macrophages have
been identified: M1 macrophages that express markers
including iNOS, CD86 and MHCII and have a neurotoxic
function and M2 macrophages that express Arginase I
and CD206 and have a neurotrophic role [7]. Following
spinal cord injury, chronic upregulation in M1 mac-
rophages is seen while the increase in M2 macrophages is
brief, lasting at most 7 days [7]. In the injured brain, acti-
vated microglia have been shown to secrete pro-inflam-
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Page 2 of 10matory cytokines such as interleukin (IL)-1β, tumor
necrosis factor (TNF) α, and IL-6 [8-11] and are involved
in phagocytosis of axonal and neuronal debris [12-14].
They have also been shown to have a neuroprotective role
following neurological insult via secretion of trophic
growth factors such as brain-derived neurotrophic factor,
glial cell line-derived neurotrophic factor and insulin-like
growth factor [15-18].
Previous studies have shown that a specific subset of
activated microglia express the lectin galectin-3/Mac-2, a
member of the galectin family of β-galactoside binding
lectins [19-21]. Within the central and peripheral nervous
system, galectin-3/Mac-2 is expressed by microglia, mac-
rophages and Schwann cells that phagocytose myelin fol-
lowing induction of experimental allergic
encephalomyelitis, ischemia, and sciatic nerve transec-
tion [20,22,23]. Galectin-3/Mac-2 is not expressed by
these cells in the intact nervous system and has not been
found within microglia in areas of inefficient myelin
phagocytosis following injury [20,22,23]. Taken together,
these studies suggest that galectin-3/Mac-2 serves as a
marker of a subpopulation of activated microglia involved
in myelin degradation.
There is emerging evidence that galectin-3/Mac-2-
immunoreactive (ir) microglia may have a role beyond
myelin phagocytosis. Following ischemic injury, galectin-
3/Mac-2 expressing microglia have been shown to
express trophic factors such as insulin-like growth factor
in the gray matter [16]. Selective ablation of galectin-3/
Mac-2 positive microglia results in an increase in the size
of the infarct zone, suggesting a neuroprotective effect of
this subset of microglia following ischemic injury [16].
In these studies, we explored whether there is up regu-
lation of galectin-3/Mac-2 immunoreactive microglia
within the corpus callosum following diffuse axonal
injury and whether these microglia are a potential source
of another trophic factor, nerve growth factor (NGF), in
the injured subcortical white matter. We specifically
chose to evaluate NGF because recent studies of human
TBI patients have found an elevation in NGF within the
cerebrospinal fluid following injury and have noted a cor-
relation between increased NGF levels and improved
clinical outcome [24,25]. We report here that after TBI,
there is chronic upregulation of galectin-3/Mac-2 immu-
noreactive microglia in the corpus callosum that persists
at 28 days following injury. Furthermore, we show that
almost all galectin-3/Mac-2 immunoreactive microglia
are immunoreactive for NGF protein in uninjured and
injured animals at all time points examined. Our findings
suggest that this subtype of activated microglia plays an
important role in the acute and chronic phases of recov-
ery following TBI that is at least in part mediated by NGF.
Methods
Animal care and housing
All experiments were performed in accordance with the
National Institutes of Health Guide for Care and Use of
Laboratory Animals. All experimental procedures were
approved by Children's Memorial Research Center Insti-
tutional Animal Care and Use Committee. Adult male
CD-1 mice weighing between 20-30 grams were used for
these experiments.
Mouse model of closed skull injury
Mice were subjected to closed skull injury using a stereot-
actically guided electromagnetic impactor (MyNeurolab,
St. Louis MO) with minor modifications of published
methods [26] as we have previously described [11]. Mice
were anesthetized with isoflurane (4% induction, 1.5%
maintenance) in 100% oxygen. Endotracheal intubation
was performed and an 18 gauge angiocatheter was
inserted as an endotracheal tube. Mice were mechanically
ventilated (Hugo Sachs Electronik, March-Hugstetten,
Germany), using a protective ventilation strategy (3 cm
H2O PEEP; tidal volume 5 cc/kg) as previously described
[27]. Core temperature was monitored using a rectal
probe (IT-18 Physitemp, NJ) and maintained at 37.0 ±
0.1°C by surface heating and cooling. Mice were secured
in prone position in a customized resin mold, and the
scalp was shaved and prepared with betadine. A midline
sagittal scalp incision was made using sterile technique,
and the periosteum reflected to reveal the appropriate
landmarks. A concave 3 mm metallic disk was affixed in
the midline, immediately caudal to bregma. The zero
depth position was determined by aligning the tip of the
impact device in the down position with the surface of
the skull. Closed skull injury was triggered using a Mat-
lab-based computer controller (MyNeuroLab.com). A
single controlled midline skull impact was delivered using
a 2.0 mm steel tip impounder at a controlled velocity (3.0
± 0.1 m/sec) and impact depth (3.0 mm). Mice with
depressed skull fracture or visible hemorrhage were
excluded from the study. After impact, the scalp incision
was sutured and mice were allowed to achieve spontane-
ous respiratory effort prior to extubation.
Histological preparation
Animals were sacrificed 1, 8, 14 or 28 days following TBI
or sham procedure (n = 5 TBI and n = 5 sham animals at
each time point). A subset of animals (n = 4) naïve to any
type of surgical procedure including isofluorane anesthe-
sia was also used as a separate control group. These latter
animals were sacrificed 3 days after arrival to the animal
facility. Mice were deeply anesthetized with a solution of
tert-amyl alcohol and 2,2,2-tribromo ethanol (0.25 ml/10
grams body weight; Sigma, St. Louis, MO). After expo-
sure of the chest cavity, animals were perfused via the left
Venkatesan et al. Journal of Neuroinflammation 2010, 7:32
http://www.jneuroinflammation.com/content/7/1/32
Page 3 of 10ventricle with 15 ml of heparinized phosphate-buffered
saline (PBS), followed by a second 15 ml perfusion with
4% paraformaldehyde in PBS. Brains were dissected from
the calvarium, immersed in 4% paraformaldehyde over-
night at 4°C and subsequently transferred to 20% sucrose
in PBS for cryoprotection. Brains were cut on a freezing
microtome at a thickness of 40 μm and collected in PBS.
The entire mouse brain was sectioned and the corpus cal-
losum was present within approximately 72 sections.
Every 12th section was used for semi-quantitative analy-
sis, yielding 5-7 sections per brain.
Immunohistochemistry (IHC)
Immunohistochemical analysis was performed on free-
floating 40-μm-thick sections. Resting and activated
microglia were identified using an antibody to IBA-1
(1:1000; Wako, Richmond, VA). Activated microglia were
identified using an antibody to galectin-3/Mac-2 (1:1000;
R and D Systems, Inc., Minneapolis, MN). Control sec-
tions were incubated in normal serum or PBS in place of
primary antibody.
Sections were rinsed in 0.01 M PBS and incubated in
1% hydrogen peroxide in PBS to quench endogenous per-
oxidase activity. Sections were rinsed again in PBS fol-
lowed by incubation in 10% blocking serum. Normal goat
serum (Vector Laboratories, Burlingame, CA) was used
for ionized calcium binding adaptor molecule 1 (IBA-1)-
IHC and normal rabbit serum (Vector) was used for
galectin-3/Mac-2-IHC. Sections were incubated with pri-
mary antibody or control solution made in the same
blocking serum with addition of 0.1% Triton-X for 48
hours at 4°C. Following incubation in primary antibody,
sections were rinsed well in PBS and incubated in bioti-
nylated secondary antibody (1:200; Vector) made in 1%
blocking serum for one hour at room temperature. Sec-
tions were rinsed in PBS prior to incubating in Vectastain
ABC solution, prepared per manufacturer's instructions.
After further PBS rinses, the reaction product was visual-
ized using diaminobenzidine substrate (DAB) as sub-
strate (Vector). Sections were rinsed in PBS, mounted on
slides and dried overnight. Slides were dehydrated in
graded ethanol solutions, followed by xylene and cover-
slipped using DPX mounting medium.
Immunofluorescence
White matter injury was assessed using an antibody to
amyloid precursor protein (APP) (1:20000; Sigma, St.
Louis, MO). Sections were rinsed well in PBS and incu-
bated in 1% hydrogen peroxide. They underwent further
PBS rinses before incubation in 10% blocking serum (nor-
mal goat serum, Vector). Following incubation in primary
antibody overnight at room temperature, sections were
rinsed well in PBS and incubated in secondary antibody
(FITC conjugated chicken anti-rabbit (1:100; ABCAM;
Cambridge, MA) made in 1% blocking serum for one
hour at room temperature. Sections were rinsed well in
PBS before mounting on slides and coverslipping with
Fluorogel (Electron Microscopy Sciences, Fort Washing-
ton, PA). Slides were stored in the dark.
Double-labeling immunofluorescence studies were per-
formed to identify which glial cell types were immunore-
active for NGF protein. Sections were rinsed well in PBS
and incubated in 1% hydrogen peroxide. They underwent
further PBS rinses before incubation in 10% blocking
serum (made in normal swine serum (Vector)). Sections
were then placed in the first primary antibody (anti-
galectin-3/Mac-2 (1:500) or anti-IBA-1 (1:500) or rabbit
anti-glial fibrillary acidic protein (GFAP)(1:2000; Dako,
Carpinteria, CA) or rabbit anti-2',3'- cyclic nucleotide 3'-
phosphodiesterase (CNPase) (1:1000; Sigma)) for 48
hours at 4°C or overnight at room temperature. After
rinsing in PBS, sections were incubated in the dark in a
solution containing the respective fluorescent secondary
antibodies in 1% blocking serum. The following second-
ary antibodies were used: FITC conjugated chicken anti-
rabbit (1:100; ABCAM) and donkey anti-goat Alexa Fluor
594 (1:100; Invitrogen Corporation, Carlsbad, CA). Fol-
lowing multiple rinses in PBS, sections were again placed
in 10% blocking serum (normal swine serum) for one
hour and then incubated in either rabbit anti-NGF (1:200;
Sigma) or goat anti-NGF (1:1000; Abcam) either for 48
hours at 4°C or overnight at room temperature. Sections
were rinsed well in PBS and incubated in the appropriate
fluorescent secondary antibody as described above. Sec-
tions were rinsed well before mounting on slides and cov-
erslipping with Fluorogel (Electron Microscopy Sciences,
Fort Washington, PA).
Control experiments for immunofluorescence studies
were carried out with omission of one or the other pri-
mary antibodies and exposure to secondary antibodies.
Experiments were also performed where a given primary
antibody (e.g. goat anti- galectin-3/Mac-2) was exposed
to the inappropriate secondary antibody (e.g. chicken
anti-rabbit). These experiments verified that the second-
ary antibody had no target antigen in the tissue and thus
provided confirmation that an inappropriate fluorescent
signal was not produced (Figure 1).
Electron microscopy processing
Animals were sacrificed after 24 hours recovery from TBI
or sham procedure. All surgical procedures were identical
to those used for light microscopy studies with the excep-
tion that a pneumatic impactor was used [11]. Qualitative
analysis of APP-ir and galectin-3/Mac-2-ir via light
microscopy confirmed no differences in the nature of
injury using the pneumatic vs. electromagnetic impactor
(data not shown). Animals underwent cardiac perfusion
with 15 ml of heparinized PBS followed by 15 ml of 4%
paraformaldehyde and 1% glutaraldehyde in PBS. Brains
were removed from the calvarium and left in the fixative
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cut on a vibratome at a thickness of 40 μm. Sections were
processed for galectin-3/Mac-2-IHC using DAB as the
chromogen as described above (immunohistochemistry)
with the exception that Triton-X was omitted from the
incubation solution. Following completion of IHC, sec-
tions were rinsed in 0.1 M phosphate buffer (PB) and
incubated in 1% osmium tetroxide for one hour and
rinsed in 0.1 M PB. Sections were sequentially dehy-
drated in graded ethanol and acetone. They were incu-
bated overnight in a mixture of Epon-812 (EMS, Hatfield,
PA) and acetone. Sections were transferred to 100%
Epon-812. Following incubation in resin for four hours,
they were flat-embedded between sheets of Aclar plastic
(EMS, Hatfield, PA) and baked in the oven at 80°C over-
night. The region of interest within the corpus callosum
was identified, cut out and embedded in BEEM capsules
(EMS, Hatfield, PA). BEEM capsules were filled with resin
and baked for 2 days at 80°C. Ultrathin sections were cut
on a Leica ultramicrotome. Sections were counterstained
with uranyl acetate and lead citrate and examined on a
JEOL 1200 EX electron microscope. Images were digitally
acquired on a Hamamatsu digital camera.
Semi-quantitative analysis of galectin-3/Mac-2 and IBA-1- 
immunoreactive cells
Semi-quantitative analysis of galectin-3/Mac-2 and IBA-
1-ir microglia was performed on every 12th section
(approximately 6 sections/animal). A Leica DMR-HC
upright research microscope with an attached QImaging
Retiga 4000R camera was used to obtain data images of
the corpus callosum using a 20 × objective. Three non-
overlapping adjacent montages encompassing the mid-
line of the corpus callosum were photographed and
stored for further analysis. Labelled cells were counted
and areal measurements were made using Image J soft-
ware. Only microglia with clearly visible cell bodies were
counted.
Qualitative and semi-quantitative analysis 
immunofluorescence labelling
Qualitative analysis of APP-ir was performed using a
Zeiss 510 META confocal laser scanning microscope at
low and high magnifications. Qualitative and semi-quan-
titative examination of double labelled fluorescent cells
was performed on the confocal microscope at 63 × mag-
nification using an oil immersion lens. For each animal,
every 12th serial section encompassing the corpus callo-
sum was analyzed, yielding approximately 6 sections/ani-
mal. For semi-quantitative analysis of galectin-3/Mac-2
and NGF labelled cells, photographs of three non-over-
lapping montages of adjacent fields centered on the cor-
pus callosum were taken with 63X oil immersion
objective and stored for off-line analyses. For each field,
photographs were taken of each data channel (e.g. galec-
tin-3/Mac-2-ir and NGF-ir) separately as well as of the
overlay image. Images were imported into Image J soft-
ware. Single-labelled galectin-3/Mac-2-ir cells and dou-
ble-labelled (galectin-3/Mac-2 and NGF-ir) cells were
scored using different markers. A total of 196 cells were
evaluated. Orthogonal reconstructions were also per-
formed with a 63X oil immersion objective to view
labelled cells in x-y, x-z and y-z cross-sectional planes to
confirm that cells were double labelled (z-step, 1 μm).
Values were exported to Excel spreadsheet and the per-
centage of double-labelled cells was calculated for each
experimental group.
Statistical analyses
Data were pooled within animals (across montages and
tissue sections) and averaged across animals within a
given experimental group. Values are expressed as mean
± SEM for each group. Two groups were compared using
Student's t-test. Significance was defined as p < 0.05.
Prism 4.0 (GraphPad Software, Inc., San Diego, CA) was
used for statistical analyses.
Figure 1 Representative images of sections from control experi-
ments of immunofluorescence labelling. Panels A and B show im-
munoreactivity within the white matter for NGF (A) and galectin-3/
Mac-2 (B). In panels C and D, sections were exposed to either goat anti-
galectin-3/Mac-2 antibody (C) or rabbit anti-NGF antibody (D), but 
were then subsequently exposed to the inappropriate secondary anti-
body (FITC chicken anti-rabbit for galectin-3/Mac-2 (C) or Alexa Fluor 
594 donkey anti-goat for NGF (D)). Panels E and F: Primary antibody 
was omitted and sections were exposed to either FITC chicken anti-
rabbit (E) or Alexa Fluor 594 donkey anti-goat (F). These experiments 
verified that secondary antibodies did not bind to an inappropriate an-
tigen in tissue sections. All tissues were from post-TBI (day 8) animals. 
Bar = 20 μm.
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Closed skull impact produces axonal injury within the 
corpus callosum
Mice were subjected to a closed-skull cortical impact or
sham procedure. A group of mice naïve to any type of
surgical intervention was also used. APP-ir has been used
to evaluate axonal damage following TBI by others [28-
32]. In our study, immunofluorescence staining for APP
showed that sham animals did not have any labelled pro-
files within subcortical white matter tracts (Figure 2). In
contrast, a punctate pattern of APP-ir, indicative of
axonal injury, was apparent within dorsal midline white
matter tracts such as the corpus callosum (Figure 2) and
the cingulum at one day following TBI. At this time point,
however, damaged axons were not noted within more lat-
erally and ventrally situated subcortical white matter
fibers including the lateral white matter tract and the
anterior commissure (Figure 2). This punctate pattern
was not evident by 8 days post-injury (Figure 2).
We used electron microscopy to evaluate ultrastruc-
tural features of damaged axons (Figure 3). Consistent
with the changes in APP-ir observed at 24 hr following
TBI, electron microscopic evaluation of the corpus callo-
sum at the same time point showed pathological changes
in the morphology of axons (Figure 3) as previously
described following TBI [30,31,33-36]. In sham animals,
ultrastructural examination of the corpus callosum
showed intact myelinated axons with preserved cytoskel-
etal detail (Figure 3A). In contrast, numerous pathologi-
cal changes were observed within the corpus callosum in
TBI animals (Figure 3B, C and 3D). Following injury,
there was separation of the myelin sheath from the axo-
lemma. Intracellular blebs or focal edematous regions
within axonal profiles were also observed. Within 24
hours following TBI, galectin-3/Mac-2-ir microglia
within the corpus callosum were noted to be engulfing
damaged axons (Figure 3B).
Increase in IBA-1 immunoreactive microglia within the 
white matter after TBI
In order to determine whether axonal injury identified in
the corpus callosum was accompanied by changes in
microglia subpopulations, we used immunohistochemi-
cal methods to detect alterations in IBA-1 immunoreac-
tivity (Figure 4). IBA-1 protein is expressed within both
active and resting microglia [16]. IBA-1-ir microglia were
scattered within the corpus callosum of both injured and
uninjured animals, but the density of IBA+ microglia was
higher following injury (Figure 4). Semi-quantitative
analysis revealed that following TBI, there was an
increase in the density of IBA-1-ir microglia at all time
points examined, reaching statistical significance on post-
injury days 1, 8 and 14 (Figure 4; cell density (cells/mm2)
± SEM; naïve: 325.7 ± 7.843; sham day 1: 298.7 ± 34.12;
TBI day 1: 314.6 ± 12.26 (p < 0.0006 vs sham day 1);; sham
day 8: 294.8 ± 5.429; TBI day 8: 433.7 ± 14.76 (p < 0.0001
vs sham day 8); sham day 14: 293.9 ± 8.873; TBI day 14:
364.9 ± 8.896 (p < 0.0001 vs sham day 14); sham day 28:
331.3 ± 7.554; TBI day 28: 348.2 ± 10.53 (p < 0.225 vs
sham day 28)).
Figure 2 Amyloid precursor protein (APP) immunoreactivity in 
sham and TBI animals. APP-ir profiles are not evident within the cor-
pus callosum (cc) in sham animals (A). One day post-TBI, prominent 
puncate labelling is present, reflecting accumulation of APP protein 
within damaged axonal endbulbs (B). This punctate pattern is not pres-
ent 8 days post-TBI here (C) or in ventrally located white matter tracts 
such as the anterior commissure (ac) (D). ctx = cortex. Bar = 100 μm.
Figure 3 Ultrastructural view of the corpus callosum in sham and 
TBI animals. In sham animals, numerous intact myelinated axons with 
preserved cytoskeletal detail can be seen (A). In contrast, pathological 
changes are present in TBI animals (B, C, and D). Galectin-3/Mac-2+ mi-
croglial cell identified by the presence of DAB reaction product (arrow-
heads) is seen engulfing an injured axon (arrow in B). An example of an 
injured axon characterized by separation of the myelin sheath from the 
axolemma is shown (arrowheads in C). Focal swelling can also be seen 
within a damaged axon (arrow in D). Bar = 500 nm in A, 2 μm in B, 500 
nm in C and D.
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within the white matter after TBI
Galectin-3/Mac-2 immunoreactivity has been shown to
be specific to a subset of activated microglia involved in
myelin phagocytosis [20,22,23]. To examine the effects of
TBI on this microglial subtype within the injured white
matter, we evaluated the pattern of galectin-3/Mac-2
labelling in the corpus callosum. First, we confirmed by
double labelling studies using anti-IBA-1 and anti-galec-
tin-3/Mac-2 antibodies that all galectin-3/Mac-2+ cells
were of microglial origin (Figure 4). Only a subpopulation
of IBA-1-ir cells expressed galectin-3/Mac-2.
Qualitative analysis clearly revealed the presence of
galectin-3/Mac-2-ir cells within the injured corpus callo-
sum that varied in density most obviously in the anterior-
posterior domain. The density of galectin-3/Mac-2+
microglia within the callosum was maximal beneath the
site of impact and decreased both anteriorly and posteri-
orly from that site (Figure 5).
Semi-quantitative evaluation showed that there was a
significant increase in galectin-3/Mac-2-ir microglia
within the injured corpus callosum that was sustained 28
days post-TBI compared to sham animals (Figure 6; cell
density (cells/mm2) ± SEM; naïve: 16.74 ± 4.253; sham
day 1: 69.11 ± 7.706; TBI day 1: 238.3 ± 38.98 90 (p <
0.0001 vs sham day 1); sham day 8: 93.13 ± 8.045; TBI day
8: 142.3 ± 14.24 (p < 0.05 vs sham day 8); sham day 14:
63.25 ± 8.516; TBI day 14: 133.5 ± 22.90 (p < 0.0001 vs
sham day 14); sham day 28: 46.04 ± 4.849; TBI day 28:
134.5 ± 19.24 90 (p < 0.0001 vs sham day 28)). The
increase was most pronounced 24 hours following injury
and was attenuated at later time points following injury
(Figure 4). Interestingly, changes in galectin-3/Mac-2-ir
microglia were also observed in sham animals. These ani-
mals were intubated and exposed to isofluorane anesthe-
sia for the same duration of time as TBI animals; however,
they only underwent skin incision, skin closure with
sutures and were allowed to recover. Sham animals had a
significant increase in galectin-3/Mac-2 labelling com-
pared to naïve animals that were not exposed to any type
of surgical procedure (Figure 4). This increase was at its
peak 8 days post-injury and declined thereafter.
Galectin-3/Mac-2-ir microglia are also immunoreactive for 
nerve growth factor protein
In order to investigate whether galectin-3/Mac-2-ir
microglia were a source of the trophic factor NGF, we
performed double labelling studies and visualized labeled
cells using confocal microscopy. NGF-ir cells were found
Figure 4 IBA-1 and Mac-2 immunoreactivity following TBI. Repre-
sentative photomicrographs showing IBA-1-ir microglia scattered 
throughout the white matter in sham (A) and 8-day post-TBI (B) ani-
mals. Semi-quantitative analysis shows statistically significant increases 
in the density of IBA-1-ir microglia 1, 8 and 14 days following injury (C). 
*,p < 0.0001; **, p < 0.006 vs. sham. Representative photomicrographs 
showing pattern of galectin-3/Mac-2 labelling in uninjured (D) and in-
jured 8 days post-TBI (E) animals. Semi-quantitative evaluation of the 
density of labeled cells confirms that following TBI, there is a significant 
increase in labelling (F) (*, p < 0.0001 vs. sham). There is also a signifi-
cant difference in the density of labelling between naïve and sham an-
imals at all time points (#, p < 0.0002 vs. sham). Bar = 100 μm in A-E. 
Representative photomicrographs illustrating microglia labeled for ga-
lectin-3/Mac-2 (G) or IBA-1 (H), and a pattern of co-localization (I). All 
galectin-3/Mac-2-labeled cells are immunoreactive for IBA-1, confirm-
ing that galectin-3/Mac-2-ir cells are microglia (arrowhead in panel G). 
However, there are IBA-1-ir cells that are not immunoreactive for galec-
tin-3/Mac-2 (arrows in panels H and I), suggesting that IBA-1 labels a 
broader population of microglia. Bar = 20 μm in G-I.
Figure 5 Spatial pattern of galectin-3/Mac-2 immunoreactive 
cells within the corpus callosum following TBI. Representative pho-
tomicrographs illustrating galectin-3/Mac-2-ir cells in the white matter 
in a TBI animal 24 after injury. Labelling within every 12th serial section 
is shown. Qualitative assessment shows that the density of galectin-3/
Mac-2 labelling is highest at the impact site (panels C and D). Labelling 
density decreases at levels both anteriorly (panels A and B) and poste-
riorly (panels E and F) from this site. Bar = 100 μm.
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all time points following injury. Qualitative evaluation of
labelling clearly showed that the density of NGF-ir cells
was higher following injury, paralleling the trend seen
with galectin-3/Mac-2 labelling. Double-labelling immu-
nofluorescence studies in tissue from both injured and
uninjured animals revealed that the majority (93-99%) of
galectin-3/Mac-2+ microglia were immunoreactive for
NGF (sham day 1: 98.3 ± 1.2%; TBI day 1: 98.9 ± 1.0% 90
(p < 0.97 vs sham day 1); sham day 8: 99.4 ± 0.6%; TBI day
8: 98.5 ± 0.9% 90 (p < 0.6 vs sham day 8); sham day 14:
93.2 ± 5.0%; TBI day 14: 97.8 ± 1.3% 90 (p < 0.89 vs sham
day 14); sham day 28: 96.0 ± 2.4%; TBI day 28: 95.5 ± 1.7%
90 (p < 0.46 vs sham day 28)) (Figure 7). However, NGF-ir
cells that were not immunoreactive for galectin-3/Mac-2
were also present.
In order to determine whether NGF protein was pres-
ent in other microglial subtypes, dual labelling immuno-
fluorescence studies were performed using the microglial
marker IBA-1. These studies identified two populations
of NGF+ cells: one population was also immunoreactive
for IBA-1 and the other was only immunoreactive for
NGF (Figure 6). We further explored whether other glial
cell types were immunoreactive for NGF. Double-label-
ling studies using an anti-CNPase antibody, a marker for
mature oligodendrocytes failed to show colocalization
between NGF and CNPase, suggesting that mature oligo-
dendrocytes were not a source of NGF protein in the cor-
pus callosum in sham and injured animals. In contrast,
there was colocalization of NGF labelling with cells
expressing the astrocytic marker GFAP (Figure 6). Thus,
in addition to galectin-3/Mac-2-ir microglia, GFAP-ir
astrocytes are also a source of NGF in the corpus callo-
sum of injured and uninjured mice.
Discussion
This study, using a murine model of closed skull diffuse
head injury, shows that there is chronic upregulation of a
sub-population of microglia immunoreactive for galec-
tin-3/Mac-2 within the corpus callosum. Ultrastructural
evaluation of the callosum using electron microscopy and
qualitative examination of APP-ir using light microscopy
both demonstrate axonal injury following this insult.
Axonal injury was confined to dorsal midline white mat-
ter tracts such as the corpus callosum and the cingulum.
Injured axons were not noted within more laterally and
ventrally situated subcortical white matter tracts such as
the anterior commissure. This may relate to the physical
proximity of the area of impact overlying the dorsal mid-
Figure 7 Galectin-3/Mac-2 immunoreactive microglia are also im-
munoreactive for NGF. Representative confocal photomicrographs 
illustrating co-localization of NGF-ir (A, arrows) and galectin-3/Mac-2-ir 
(B, arrows) microglia in an animal 7 days post-injury. Image overlay of 
NGF and galectin-3/Mac-2 labelling shows that the majority of galec-
tin-3/Mac-2+ microglia are also immunoreactive for NGF. Semi-quan-
titative evaluation of percentage of double-labeled cells in all 
experimental groups confirms the qualitative observation; 93-99% of 
all galectin-3/Mac-2+ microglia are immunoreactive for NGF (D). Bar = 
20 μm in A-C. Orthogonal reconstructions (E-G) from confocal z-series 
in x-z (top) and y-z (right) planes confirm that NGF-ir and galectin-3/
Mac-2-ir are present within the same cell (arrows).
Figure 6 Colocalization of NGF-ir cells with IBA-1-ir microglia and 
GFAP-ir glia. Panels A-C show representative photomicrographs illus-
trating co-localization of IBA-1-ir (A) and NGF-ir (B) cells. Image overlay 
of NGF and IBA-1 labelling is shown in panel C. While the majority of 
cells are immunoreactive for both IBA-1 and NGF (arrows in A, B, and 
C), NGF-ir cells that are not IBA-1+ are also present (arrowhead in B and 
C). Bar = 20 μm in A-C. Orthogonal reconstructions from confocal z-se-
ries in x-z (top) and y-z (right) planes confirm that there is colocalization 
of IBA-1-ir and NGF-ir (D-F, arrows). Similar orthogonal reconstructions 
show colocalization of GFAP-ir and NGF-ir cells (G-I, arrows).
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within the injured white matter in the setting of diffuse
axonal injury is consistent with the previously identified
role for these microglia in myelin phagocytosis following
central nervous system inflammation [20,22,23]. We also
show that this subpopulation of microglia is immunore-
active for nerve growth factor in naïve, sham and injured
animals at all time points examined. Our findings suggest
that galectin-3/Mac-2-ir microglia are involved in the
pathogenesis of diffuse axonal injury both acutely and
chronically and that they mediate their effects, at least in
part by releasing NGF.
The increase in activated microglia identified by galec-
tin-3/Mac-2 appears to vary with the type and severity of
neurologic insult. Previous studies have reported the
presence of galectin-3/Mac-2 expressing microglia at
sites of neuronal damage following hypoxia-ischemia
injury [20], but not after facial nerve axotomy [20]. The
authors observed that these two models differ in the
degree of severity of injury and concluded that galectin-
3/Mac-2 expression correlates with microglial activation
in response to severe trauma [20]. In the murine periph-
eral nervous system, sciatic nerve transection induces
Schwann cells to express galectin-3/Mac-2 and phagocy-
tose myelin [22].
A number of lines of evidence support a role for this
population of microglia in the mechanisms of phagocyto-
sis following cerebral injury. It has been proposed that
Mac-2 mediates myelin phagocytosis in the periphery
through a non-immune, opsonin-independent mecha-
nism referred to as lectinophagocytosis [22]. In support
of a role for galectin-3/Mac-2 in active myelin phagocyto-
sis, it was shown in a model of optic nerve injury, where
myelin degradation and phagocytosis proceed slowly, that
only a small subpopulation of microglia express galectin-
3/Mac-2 [14]. In contrast, after experimental allergic
encephalomyelitis in mice, sites of demyelination within
the spinal cord and optic nerve with active myelin degen-
eration and phagocytosis displayed robust expression of
galectin-3/Mac-2 by resident microglia [23]. In vitro
studies further support a role for galectin-3/Mac-2
expressing microglia in myelin phagocytosis [21,23,37].
In our studies, galectin-3/Mac-2-ir microglia are robustly
upregulated within the corpus callosum following diffuse
TBI, and we find ultrastructural evidence one day follow-
ing injury that these microglia engulf damaged axons.
This finding supports at least one specific role for galec-
tin-3/Mac-2-ir microglia acutely following diffuse axonal
injury, the phagocytosis of myelin in this injury model as
well.
There is emerging evidence that galectin-3/Mac-2-
expressing microglia have roles beyond myelin phagocy-
tosis. Selective ablation of galectin-3/Mac-2-positive
microglia in transgenic mice was associated with an
increase in the size of the infarct zone following transient
middle cerebral artery occlusion [16]. Further, galectin-3/
Mac-2-ir microglia expressed insulin-like growth factor
(IGF), suggesting that this subset of microglia has a neu-
roprotective role via secretion of trophic growth factors
[16]. Long term upregulation of both IBA-1-ir and galec-
tin-3/Mac-2-ir microglia has also been observed in the
subventricular zone (SVZ) following middle cerebral
artery occlusion [18]. IBA-1-ir microglia in these studies
colocalize IGF, which supports a neuroprotective and
supportive role for microglia in the generation of neuro-
blasts within the SVZ [18].
Our results identifying a subset of galectin-3/Mac-2-ir
microglia also immunoreactive for the neurotrophic fac-
tor NGF, support a dual role. NGF has been shown to be
elevated in cerebrospinal fluid of children following trau-
matic brain injury [24,25]. These studies noted a correla-
tion between NGF level and outcome; better clinical
outcome was correlated with higher NGF levels [24,25]
suggesting that NGF may have a beneficial role in neu-
ronal repair. Experimental studies of exogenous neu-
rotrophin administration show beneficial effects on axon
sprouting, neuronal survival and oligodendrocyte prolif-
eration [38-43].
However, there is also evidence for a detrimental role
for NGF and its precursor proNGF. NGF has been impli-
cated in the etiology of autonomic instability present
after spinal cord injury, which can be blocked by intrathe-
cal administration of neutralizing antibody to NGF or
trkA-IgG fusion protein that binds NGF [44,45]. NGF's
growth-promoting effects are mediated via binding and
activation of high affinity trkA Neurotrophin receptor
[for review, see [46]]. In the absence of trkA, NGF binds
to its low affinity receptor p75NTR, which is thought to
be responsible for triggering death pathways [47]. Pro-
NGF, which binds with high affinity to p75NTR, and
NGF have been implicated in p75NTR-mediated oligo-
dendrocyte death in the retina and spinal cord [48-51].
Our studies find both an acute increase in galectin-3/
Mac-2+/NGF+ microglia 1 day following injury as well as
a relatively attenuated chronic upregulation of this popu-
lation of microglia even 28 days following injury. It is not
clear whether the functional properties of this microglial
subpopulation remain the same during the acute and
chronic phases of injury. It is possible that the effector
functions of NGF depend on the populations of mature
oligodendrocyte and oligodendrocyte precursors present
at various time frames following injury and the neurotro-
phin receptors found on these cells.
Our study also found a statistically significant increase
in galectin-3/Mac-2-ir microglia within the corpus callo-
sum in animals exposed to sham surgery when compared
to naïve animals; however, this increase in labelling in
sham animals was still significantly lower than that seen
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increase is not readily apparent, but may involve a gener-
alized stress response to the sham surgical procedure.
Morphological, but not functional activation of microglia
within the central nervous system has been noted in
rodents following restraint stress and immersion of body
in water [52].
Conclusions
The results from this study, using an in vivo model of
closed skull injury, provide further evidence that specific
populations of microglia are differentially activated in
response to brain. We show that following diffuse TBI,
activated microglia expressing the lectin galectin-3/Mac-
2 are chronically upregulated within the corpus callosum.
Furthermore, the majority of these microglia are immu-
noreactive for nerve growth factor. Our results support
the growing body of evidence that there are heterogenous
subpopulations of microglia, which secrete different neu-
ral effectors including growth factors at varying points
following injury. The elucidation of the mechanisms by
which microglia are activated and contribute to mecha-
nisms of injury or repair following TBI will be essential if
activated microglia are to serve as a therapeutic target for
reducing neurologic morbidity associated with white
matter injury after head injury.
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